NO790512L - Fremgangsmaate ved fremstilling av et enzym fra bakteriekilder og farmasoeytiske komposisjoner som inneholder dette - Google Patents
Fremgangsmaate ved fremstilling av et enzym fra bakteriekilder og farmasoeytiske komposisjoner som inneholder detteInfo
- Publication number
- NO790512L NO790512L NO790512A NO790512A NO790512L NO 790512 L NO790512 L NO 790512L NO 790512 A NO790512 A NO 790512A NO 790512 A NO790512 A NO 790512A NO 790512 L NO790512 L NO 790512L
- Authority
- NO
- Norway
- Prior art keywords
- glycohydrolase
- pharmaceutical compositions
- virus
- acetylmuramine
- enzyme
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 10
- 102000004190 Enzymes Human genes 0.000 title description 24
- 108090000790 Enzymes Proteins 0.000 title description 24
- 238000002360 preparation method Methods 0.000 title description 2
- 230000001580 bacterial effect Effects 0.000 title 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 49
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 49
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 17
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 9
- 125000003047 N-acetyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 37
- 230000000694 effects Effects 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 239000000243 solution Substances 0.000 description 14
- 241000282339 Mustela Species 0.000 description 13
- 102000005348 Neuraminidase Human genes 0.000 description 13
- 108010006232 Neuraminidase Proteins 0.000 description 13
- 235000013601 eggs Nutrition 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 230000035931 haemagglutination Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 5
- 239000001166 ammonium sulphate Substances 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 206010022000 influenza Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- MNLRQHMNZILYPY-MKFCKLDKSA-N N-acetyl-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MKFCKLDKSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 241000193468 Clostridium perfringens Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000192017 Micrococcaceae Species 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000007981 phosphate-citrate buffer Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 102000009133 Arylsulfatases Human genes 0.000 description 1
- 101000588395 Bacillus subtilis (strain 168) Beta-hexosaminidase Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000014085 Chronic respiratory disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH171978 | 1978-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO790512L true NO790512L (no) | 1979-08-17 |
Family
ID=4216998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO790512A NO790512L (no) | 1978-02-16 | 1979-02-15 | Fremgangsmaate ved fremstilling av et enzym fra bakteriekilder og farmasoeytiske komposisjoner som inneholder dette |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0004214A1 (el) |
| JP (1) | JPS54147911A (el) |
| AR (1) | AR219372A1 (el) |
| AU (1) | AU4427879A (el) |
| BR (1) | BR7900951A (el) |
| DD (1) | DD141903A5 (el) |
| DE (1) | DE2905678A1 (el) |
| DK (1) | DK64379A (el) |
| FI (1) | FI790483A (el) |
| GR (1) | GR68088B (el) |
| IL (1) | IL56679A0 (el) |
| NO (1) | NO790512L (el) |
| OA (1) | OA06185A (el) |
| PL (1) | PL213477A1 (el) |
| PT (1) | PT69235A (el) |
| ZA (1) | ZA79697B (el) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU662152B2 (en) * | 1991-04-09 | 1995-08-24 | Signal Coordinating Therapy, Inc. | Method for treating herpes infections |
| DE69122105T2 (de) * | 1991-11-05 | 1997-02-06 | Technochemical Corp S A | Verfahren zur Erlangen von Monosialogangliosiden |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2262962B1 (el) * | 1974-03-05 | 1977-11-04 | Science Union & Cie | |
| DE2620649C3 (de) * | 1976-05-11 | 1980-11-06 | Behringwerke Ag, 3550 Marburg | Immunologisches Adjuvans |
-
1979
- 1979-02-14 FI FI790483A patent/FI790483A/fi unknown
- 1979-02-14 DE DE19792905678 patent/DE2905678A1/de not_active Withdrawn
- 1979-02-14 GR GR58367A patent/GR68088B/el unknown
- 1979-02-15 AU AU44278/79A patent/AU4427879A/en not_active Abandoned
- 1979-02-15 ZA ZA79697A patent/ZA79697B/xx unknown
- 1979-02-15 EP EP79400094A patent/EP0004214A1/fr not_active Withdrawn
- 1979-02-15 BR BR7900951A patent/BR7900951A/pt unknown
- 1979-02-15 JP JP1669279A patent/JPS54147911A/ja active Pending
- 1979-02-15 IL IL56679A patent/IL56679A0/xx unknown
- 1979-02-15 AR AR275518A patent/AR219372A1/es active
- 1979-02-15 PT PT7969235A patent/PT69235A/pt unknown
- 1979-02-15 NO NO790512A patent/NO790512L/no unknown
- 1979-02-15 DK DK64379A patent/DK64379A/da not_active Application Discontinuation
- 1979-02-16 OA OA56736A patent/OA06185A/xx unknown
- 1979-02-16 DD DD79211058A patent/DD141903A5/de unknown
- 1979-02-16 PL PL21347779A patent/PL213477A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2905678A1 (de) | 1979-12-20 |
| GR68088B (el) | 1981-10-30 |
| IL56679A0 (en) | 1979-05-31 |
| OA06185A (fr) | 1981-06-30 |
| EP0004214A1 (fr) | 1979-09-19 |
| BR7900951A (pt) | 1979-09-11 |
| DK64379A (da) | 1979-08-17 |
| PT69235A (fr) | 1979-03-01 |
| FI790483A (fi) | 1979-08-17 |
| DD141903A5 (de) | 1980-05-28 |
| JPS54147911A (en) | 1979-11-19 |
| PL213477A1 (el) | 1979-12-03 |
| AU4427879A (en) | 1979-08-23 |
| AR219372A1 (es) | 1980-08-15 |
| ZA79697B (en) | 1980-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2172543B1 (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| RU2162710C2 (ru) | Вакцина против свиного и репродуктивного и респираторного синдрома | |
| CN111658664B (zh) | 海参多糖在抗新型冠状病毒中的应用 | |
| US4338296A (en) | Influenza virus and process of producing a vaccine therefrom | |
| CN111420044A (zh) | 一种四价流感病毒亚单位疫苗及其制备方法 | |
| CN113583981A (zh) | 一种鸡胚培养法来源的流感病毒纯化方法、四价流感病毒亚单位疫苗及其应用 | |
| CN108452298A (zh) | 一种用spf鸡胚细胞生产黄热病减毒活疫苗的工艺 | |
| CN112717128B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
| CN108210922A (zh) | 一种新型的细胞免疫增强佐剂 | |
| CN104888213A (zh) | 一种猪瘟脾淋源复合活疫苗的制备方法 | |
| CN114377127B (zh) | 一种三联卵黄抗体制剂及其制备方法和应用 | |
| NO790512L (no) | Fremgangsmaate ved fremstilling av et enzym fra bakteriekilder og farmasoeytiske komposisjoner som inneholder dette | |
| CN116121202B (zh) | 一种柯萨奇病毒b组1型毒株及应用 | |
| CN1845756A (zh) | 用于治疗疱疹感染的方法和组合物 | |
| CN104873978A (zh) | 一种猪瘟脾淋源活疫苗用冻干保护剂 | |
| US4278662A (en) | Attenuated influenza type A virus vaccine | |
| CN112080478B (zh) | 一种h5亚型禽流感病毒的高效增殖方法及应用 | |
| CA2178553A1 (en) | Marek's disease vaccine | |
| CN111057683A (zh) | 一种鸡胚接种用病毒稀释液及其制备方法和应用 | |
| JP2007068401A (ja) | 西ナイルウイルスワクチン | |
| CN116615234A (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
| CN111777684A (zh) | 冠状病毒串联表位蛋白所诱导抗体的制备方法及其应用 | |
| SE431400B (sv) | Lactobacterium acidophilum-heterovaccin for terapeutisk behandling av trikomonasinfektion | |
| CN112791179B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
| CN113249339B (zh) | 一种h3亚型犬流感病毒株、灭活疫苗及其制备方法 |